Empirical Antibiotic Therapy With Biapenem For Febrile Neutropenic In Patients With Hematological Malignancy

Objective: To evaluate the clinical efficacy and safety of empiricalantibiotic therapy with biapenem for febrile neutropenic patients withhematological malignancy.Methods: We conducted a retrospeotive study, eighty-sevenhematological malignancy patients with febrile neutropenic were identifiedin our department between March2011and December2013.They weregiven0.3g biapenem for2times a day intravenously. During the treatment,we observed the changes of temperature, clinical manifestation, laboratoryexamination in patients and to evaluate the clinical efficacy, side effects,bacterial eradication rate and infection associated mortality.Results: The total clinical effective rate was73.56%. These patientswho remain neutropenic for≤7days were higher effective rate thanpatients who expected to be neutropenic for＞7days,81.82%vs56.25%,P＜0.05, the rate of pathogenic organisms were isolated from patients was14.94%, the bacterial eradication rate was76.92%, the adverse reactionincidence was3.45%, the infection associated mortality was0%. Conclusion: Biapenem is a safe and effective drug for febrileneutropenic in patients with hematological malignancy.